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therosclerosis on the Development
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utcomes in Heart Transplant Recipients
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on A. Kobashigawa, MD,† Jonathan M. Tobis, MD†
eijing, China; and Los Angeles, California
OBJECTIVES This study sought to evaluate the influence of donor lesions on the development of cardiac
allograft vasculopathy and outcomes in heart transplant recipients.
BACKGROUND After orthotopic heart transplantation (OHT), coronary artery narrowing occurs as a
combination of pre-existing donor lesions and new lesions that develop as a result of cardiac
allograft vasculopathy.
METHODS Intravascular ultrasound (IVUS) studies were performed in 301 recipients at 1.3  0.6
months and again at 12.2  0.8 months after OHT. Additional IVUS studies were
performed in 90 patients at two and three years of follow-up. Sites at baseline with maximum
intimal thickness 0.5 mm were defined as pre-existing donor lesions. The angiographic
diagnosis of transplant coronary artery disease (TCAD) was defined as a new50% diameter
narrowing of a major epicardial vessel.
RESULTS Donor lesions were present in 30% of the hearts. By IVUS, sites with donor lesions did not
have a greater increase in intimal area compared with sites without donor lesions.
Angiographically, the incidence of TCAD up to three years after transplantation was higher
in recipients with donor lesions than in recipients without donor lesions (25% vs. 4%, p 
0.001). However, the three-year mortality rate was similar between recipients with or without
donor lesions (4.5% vs. 5.2%, p  1.0).
CONCLUSIONS Pre-existing donor lesions do not act as a nidus for accelerating the progression of intimal
hyperplasia. However, patients with donor lesions have a higher incidence of angiographic
TCAD. Donor lesions do not affect the long-term survival of patients with OHT up to three
years. (J Am Coll Cardiol 2006;47:2470–6) © 2006 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.01.072Cardiology Foundation
d
v
d
t
d
i
p
s
s
a
v
r
M
P
a
t
p
t
i
3
b
iransplant coronary artery disease (TCAD) is the primary
imitation to long-term survival of heart transplant recipi-
nts (1–4). After orthotopic heart transplantation (OHT),
oronary artery narrowing is caused by a combination of
re-existing donor atherosclerosis and new lesions that
evelop as a result of cardiac allograft vasculopathy. Angio-
raphic evidence of TCAD is present in 42% of heart
ransplant recipients at five years (5). After five years,
CAD and late graft failure (likely caused by allograft
asculopathy) together account for 30% of all OHT deaths
6). The prevalence of atherosclerosis in the donor pool is
igh (7,8). When sites with a maximum intimal thickness
0.5 mm are defined as atherosclerotic, the presence of
onor atherosclerosis varies from 17% in individuals 20
ears old, to 28% in subjects 30 years old, and by age 40,
70% of individuals show 1 coronary artery site with
onor atherosclerosis (7). With increasing demand for
ardiac transplantation and a decreasing donor pool, more
earts with pre-existing donor atherosclerosis are being
ransplanted; thus the long-term impact of pre-existing
From the *Department of Cardiology, Peking University Third Hospital, Beijing,
hina; and the †Department of Medicine, Division of Cardiology, University of
alifornia Los Angeles, David Geffen School of Medicine, Los Angeles, California.a
Manuscript received November 23, 2005; revised manuscript received January 10,
006, accepted January 16, 2006.onor atherosclerosis becomes an important concern. Pre-
ious studies show a relationship of older donor age to the
evelopment of TCAD and poor survival after cardiac
ransplantation (2,9–12). It is unclear whether pre-existing
onor atherosclerosis predisposes the recipients to develop-
ng accelerated TCAD. It is also uncertain whether the
resence of pre-existing donor atherosclerosis affects the
urvival of heart transplant recipients. The objective of this
tudy was to evaluate the influence of pre-existing donor
therosclerosis on the development of cardiac allograft
asculopathy and clinical outcomes in cardiac transplant
ecipients.
ETHODS
atient population. The current study is a retrospective
nalysis of the intravascular ultrasound (IVUS) core labora-
ory images combined from several clinical trials. Only
atients who survived the first year after heart transplanta-
ion and had baseline and one-year IVUS studies were
ncluded in the present study. The population consisted of
01 patients who underwent de novo heart transplantation
etween 1992 and 1997. All recipients received triple
mmunosuppression, consisting of cyclosporine, prednisone,
nd azathioprine or mycophenolate mofetil during the first
y
p
a
a
p
p
A
6
i
c
o
9
a
b
l
i
p
c
d

I
p
o
p
o
u
i
s
g
u
3
i
d
w
t
p
l
I
a
I
c
I
(
C
c
m
a
b
m
c
c
w
i
s
I
f
i
s
s
s
c
d
v
t
a
s
t
w
fi
u
m
d
d
w
o
a
p
C
p
m
d
p
S
t
a
v
w
r
l
t
e
b
l
b
w
b
w
t
d
p
t
2471JACC Vol. 47, No. 12, 2006 Li et al.
June 20, 2006:2470–6 Heart Transplant IVUS Studyear after transplantation. One hundred ninety of these
atients were in a trial that randomized them to either
zathioprine or mycophenolate mofetil. The trials were
pproved by the institutional review board of each partici-
ating center, and informed consent was obtained from all
atients.
ngiography. Coronary angiograms were performed within
to 8 weeks after transplantation and subsequently at annual
ntervals. Multiple angiographic views of the right and left
oronary arteries were obtained. Of the 301 patients, 100% of
ne-year survivors, 94% (273 of 291) of two-year survivors, and
0% (256 of 286) of three-year survivors underwent serial
ngiography studies. The angiographic reports were performed
y quantitative coronary angiography at an independent core
aboratory. Cine film recording used a six- to eight-inch image
ntensifier mode. The recordings of contrast-filled catheters
rovided scaling factors for measuring luminal diameters via
omputerized vessel edge detection software. The angiographic
iagnosis of TCAD was based on observing a new lesion
50% diameter narrowing of a major epicardial vessel.
VUS imaging procedure. The IVUS examinations were
erformed in all patients within six to eight weeks and at
ne year after transplantation. Of the 301 recipients, 90
atients had additional IVUS studies at two and three years
f follow-up. After full anticoagulation with heparin 100
nits/kg, a guide catheter was advanced over a guidewire
nto the selected coronary artery. Patients received 0.4 mg
ublingual nitroglycerin and/or 200 g intracoronary nitro-
lycerin before advancing the IVUS catheter. A 30-MHz
ltrasound transducer (4.3-F, CVIS, Sunnyvale, California;
.5-F, Hewlett-Packard, Palo Alto, California) was inserted
nto a distal position of the selected vessel where the luminal
iameter exceeded 2 mm. A manual slow (30 s) pullback
as performed from the distal position to the proximal site of
he coronary artery. The dates of inclusion into the study
receded the use of automated pullback devices. The catheter
ocation was recorded with cine angiography. Continuous
VUS images were recorded on S-VHS videotape with voice
nnotation.
VUS imaging analysis. The IVUS tapes were sent to a
ore laboratory that was blinded to patient treatment. The
VUS images were digitized by the echoPlaque program
echoPlaque version 2.5, INDEC Systems, Santa Clara,
alifornia). Landmarks for IVUS such as side branches,
alcification, pericardium, and cardiac veins were used in
atching the sites. Two to four matched sites from each
rtery were chosen using side-by-side comparison of the
Abbreviations and Acronyms
EEM  external elastic membrane
IVUS  intravascular ultrasound
MIT  maximum intimal thickness
OHT  orthotropic heart transplantation
TCAD  transplant coronary artery diseaseaseline and follow-up images. These sites included the left sain and the proximal, middle, and distal sites of each
oronary artery. Frames during the diastolic phase of the
ardiac cycle were selected for measurement. The frame
ith the most severe intimal thickening from each site was
dentified in the first-year IVUS study after OHT. These
elected frames were matched with sites from the baseline
VUS study. For the IVUS studies obtained at three-year
ollow-up, the frame with the most severe intimal thicken-
ng from each site was identified in the third-year IVUS
tudy, and then these selected frames were matched with
ites from baseline and the first- and second-year IVUS
tudies. Only sites that had clear matching identifiers were
hosen for analysis. Luminal and vessel contours were
rawn with the planimetry software on each cross-sectional
iew by manually tracing the border between the intima and
he lumen, and the boundary between the media and
dventitia at the external elastic membrane (EEM). In each
ite, maximum intimal thickness (MIT), intimal area, ex-
ernal elastic membrane area (EEM area), and lumen area
ere measured. The cross-sectional area stenosis was de-
ned as (intimal area/EEM area)  100%.
The following definitions for lesion characteristics were
sed: donor lesions were defined as sites with MIT 0.5
m at baseline study. At one year after transplantation,
onor lesions with an increase 0.5 mm in MIT were
efined as progression of donor lesions, and donor lesions
ith a decrease0.5 mm inMIT were defined as regression
f donor lesions. New lesions were defined as lesions with
n increase in MIT 0.5 mm at one year that had a
revious baseline MIT 0.5 mm.
linical events. Patients were classified as having end
oint events if they had any of the following within 36
onths after transplantation. The primary end point was
eath from any cause. The secondary end point was the
resence of TCAD confirmed by angiography.
tatistical analysis. Descriptive statistics were presented as
he mean value  standard deviation for continuous vari-
bles and as frequencies and percentages for categorical
ariables. Comparisons between baseline and follow-up
ere determined by paired t test. For comparisons between
ecipients of hearts with or without pre-existing donor
esions, the clinical characteristics were analyzed with use of
he Independent t test for continuous variables and Fisher
xact or chi-square tests for categorical data. Differences
etween sites with progression of donor lesions or with new
esions were tested by the Independent t test. Comparisons
etween three groups (sites with or without donor lesions)
ere performed using one-way analysis of variance followed
y multiple comparisons with Bonferroni correction if this
as significant. Survival analysis was performed by applying
he Kaplan-Meier method. Differences in survival of free-
om from TCAD between recipients with or without
re-existing donor lesions were assessed using the log-rank
est. A two-sided p value  0.05 was considered statistically
ignificant.
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atient enrollment. A total of 301 de novo cardiac trans-
lant recipients (248 men, 53 women; mean age 52.5  9.2
ears) with three-year follow-up were analyzed. The IVUS
maging was performed in all recipients at 1.3 0.6 months
nd again at 12.2 0.8 months after OHT. The 1,103 sites
rom 333 coronary arteries (mean 3.3 sites per artery) were
atched by IVUS imaging between the two studies approx-
mately one year apart. Of the 333 coronary arteries, there
ere 254 left anterior descending arteries, 55 left circumflex
rteries, and 24 right coronary arteries. The mean donor age
as 29.6  12.7 years (range 11 to 67 years). In addition,
04 sites from 90 arteries were matched from baseline to the
hird year after transplantation.
revalence and progression of donor lesions. Donor
esions were shown at 196 sites from 96 arteries in 89 (30%)
f the 301 hearts. At one-year follow-up, of the 196 sites
ith donor lesions, 16 (8%) showed progression of intimal
yperplasia on the donor lesion, 5 (3%) sites showed
egression of donor lesions, and 175 (89%) sites had an
able 1. Clinical Characteristics of Recipients
Characteristics
Recip
aseline demographics
Donor age (yrs)
Recipient age (yrs)
Recipient female gender
HLA mismatch
Pretransplantation CAD
Recipient with CMV mismatch (D/R)
Cold ischemic time (h)
isk factors
Cholesterol, mean value during the first yr (mg/dl) 2
Diabetes
Hypertension
he use of medications
Statins
Calcium blockers
Azathioprine at yr 1
ejection 3A or higher grade at yr 1
alues are n (%) or mean  SD.
CAD  coronary artery disease; CMV  cytomegalovirus; D  donor positiv
able 2. IVUS Parameters at the First Year After Transplantatio
Parameters
Arteries Wi
Sites With DL (Group 1)
(n  196)
MIT (mm) 0.06  0.30
IA (mm2) 0.54  2.08
LA (mm2) 0.89  2.97
EEM area (mm2) 0.35  2.67
A/EEM area (%)
Baseline 31.33  12.88
Yr 1 33.82  13.69
Yr 1 to baseline 2.49  10.47
value, using one-way analysis of variance followed by multiple comparisons with B
.001, compared group 3 with 1. p  0.001, compared group 3 with 2.
DL  donor lesions; EEM  external elastic membrane; IA  intimal area; IA/EEM
rea; MIT  maximum intimal thickness.bsolute change 0.5 mm in maximum intimal thickness.
he mean age of the 89 donor hearts with donor lesions was
9.5  10.1 years, as compared with a mean age of 25.4 
1.2 years in 212 hearts without donor lesions (p  0.001).
he other clinical characteristics were similar between
ecipients of hearts with or without pre-existing donor
esions (Table 1).
ne-year IVUS data in 301 patients. To further catego-
ize the effect of pre-existing donor atherosclerosis in the
eart transplant patients, the 1,103 sites were divided into
hree groups: 1) 196 (18%) sites with donor lesions; 2) 179
16%) sites without donor lesions but from arteries with a
onor lesion; and 3) 728 (66%) sites without donor lesions
rom arteries without donor lesions (Table 2). Because all
hree major epicardial arteries were not imaged with IVUS,
e cannot be certain whether the sites from arteries without
onor lesions also came from hearts without donor lesions
n any other arteries. The average increase in maximum
ntimal thickness and cross-sectional area stenosis from
aseline to 12 months was smaller in donor lesions than in
With DL
89)
Recipients Without DL
(n  212) p
10.1 25.4  11.2 0.001
7.6 52.2  9.7 0.3
6.9) 53 (25.0) 0.1
1.32 4.53  1.37 0.5
2.8) 111 (52.4) 1.0
6.9) 23 (10.8) 0.3
0.9 3.0  0.9 0.2
39.3 206.9  39.7 0.7
7.1) 91 (42.9) 0.3
1.0) 204 (96.2) 0.1
1.8) 116 (54.7) 0.3
8.5) 161 (75.9) 0.2
7.4) 132 (62.3) 0.4
9.4) 107 (50.5) 0.9
 donor lesions; R  recipient negative; HLA  human leukocyte antigen.
Arteries Without DL
es Without DL (Group 2)
(n  179)
Sites Without DL (Group 3)
(n  728)
0.14  0.22* 0.11  0.21‡
0.90  1.60 0.75  1.46
0.65  2.42 0.74  2.82
0.25  2.32 0.01  2.85
12.57  5.43† 9.61  3.97§
17.96  10.51† 14.02  9.00§
5.39  8.82* 4.41  8.07‡
oni correction. *p  0.01, †p  0.001, compared group 2 with 1. ‡p  0.05, §p ients
(n 
39.5 
53.3 
15 (1
4.64 
47 (5
15 (1
2.8 
08.9 
33 (3
81 (9
55 (6
61 (6
60 (6
44 (4n
th DL
Sit
onferrarea  cross-sectional area stenosis; IVUS  intravascular ultrasound; LA  lumen
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June 20, 2006:2470–6 Heart Transplant IVUS Studyhe two groups without donor lesions (p  0.05). However,
he cumulative cross-sectional area stenosis was larger in
onor lesions than in the two groups without donor lesions
t the first year after transplantation (p  0.001).
At the first year, a total of 51 sites from 38 arteries
eveloped new lesions in 36 (12%) of the 301 hearts. Of the
1 sites, 12 sites came from 9 (9%) of the 96 arteries with
onor lesions and 39 sites came from 29 (12%) of the 237
rteries without baseline lesions (p 0.5). Of the 96 arteries
ith donor lesions, 14 (15%) arteries had donor lesion
rogression and 82 (85%) did not show progression. New
esions were present in 2 (14%) of the 14 arteries that
howed progression, and in 7 (9%) of the 82 arteries without
onor lesion progression (p 0.6). As shown in Table 3, for
he same degree of increase in intimal area, the EEM of the
essel enlarged in new lesions, whereas sites with progres-
ion of donor lesions had no significant change in EEM
rea.
hree-year IVUS data in 90 patients. Of the 304 sites
atched from baseline to three-year follow-up: 1) 45 (15%)
ites had donor lesions; 2) 38 (13%) sites did not have donor
esions but came from arteries with a donor lesion present;
nd 3) 221 (72%) sites did not have donor lesions and came
rom arteries without donor lesions (Table 4). No significant
ifferences were found in the average change in maximum
ntimal thickness, intimal area, or cross-sectional area ste-
osis among the three groups during the three-year follow-
able 3. IVUS Parameters in Sites With Progression of Donor
esions and Sites With New Lesions at the First Year After
ransplantation
Parameters
Progression of DL
(n  16)
New Lesions
(n  51) p
MIT (mm) 0.71  0.18* 0.73  0.23* 0.7
IA (mm2) 4.15  2.83* 4.47  2.07* 0.6
LA (mm2) 4.05  2.30* 3.54  2.75* 0.5
EEM area (mm2) 0.10  2.02 0.93  2.62† 0.3
(IA/EEM area) (%) 19.05  9.29* 25.29  10.87* 0.04
p  0.001; †p  0.05, baseline compared with the first year after transplantation.
Abbreviations as in Table 2.
able 4. IVUS Parameters During the 3-Year Follow-Up
Parameters
Arterie
Sites With DL (Group 1)
(n  45)
hange in MIT (mm)
Yr 1 to baseline 0.14  0.24
Yr 2 to yr 1 0.02  0.37
Yr 3 to yr 2 0.07  0.24
hange in IA (mm2)
Yr 1 to baseline 1.01  2.14
Yr 2 to yr 1 0.02  1.99
Yr 3 to yr 2 0.59  1.31
hange in (IA/EEM area) (%)
Yr 1 to baseline 4.09  10.14
Yr 2 to yr 1 3.58  11.16
Yr 3 to yr 2 3.05  6.62 0.05 for overall comparison by one-way analysis of variance.
Abbreviations as in Table 2.p. Similar to the IVUS findings at the first year, the
umulative cross-sectional area stenosis was larger in donor
esions than in the two groups without donor lesions from
aseline to three-year follow-up, p  0.01 (Fig. 1). The
ncidence of angiographic TCAD was higher in recipients
ith donor lesions (25%) than in recipients without donor
esions (4%) at a mean 33.5  6.7 months of follow-up,
 0.001 (Fig. 2). However, a similar rate of progression of
ross-sectional area stenosis by IVUS was found between
onor lesions and the two groups without donor lesions
Fig. 3). Angiographically significant coronary narrowing
50% diameter stenosis) will be reached sooner in patients
ith donor lesions because they start at a higher percent
tenosis.
urvival. By three years after transplantation, 4 (4.5%) of the
9 recipients with donor lesions died (1 cardiovascular event, 1
ulmonary embolism, and 2 unknown cause). In the 212
igure 1. Bar graphs show that the cumulative cross-sectional area of
tenosis was larger in donor lesions than in the two groups without donor
esions up to three years after transplantation (all p  0.001). In sites
ithout donor lesions, the cumulative cross-sectional area of stenosis was
arger in arteries with donor lesions than in arteries without donor lesions
p to three years after transplantation (all p  0.01). The p value used
ne-way analysis of variance, followed by multiple comparisons with
onferroni correction. DL  donor lesions; Without DL (1)  sites
ithout donor lesions but from arteries with donor lesions; Without DL
2)  sites without donor lesions from arteries without donor lesions.
th DL Arteries Without DL
Sites Without DL (Group 2)
(n  38)
Sites Without DL (Group 3)
(n  221)
0.15  0.21 0.08  0.18
0.0003  0.17 0.04  0.14
0.07  0.19 0.06  0.18
0.93  1.56 0.56  1.37
0.20  1.47 0.31  0.92
0.57  1.33 0.33  1.04
4.97  9.41 3.24  5.96
1.95  9.35 2.49  6.23
2.67  8.74 1.59  5.57s Wi
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Heart Transplant IVUS Study June 20, 2006:2470–6ecipients without donor lesions, 11 (5.2%) patients died
4 cardiovascular events, 2 rejections, 1 infection, 1 pulmonary
mbolism, 1 cancer, and 2 of unknown cause). The three-year
ortality rate was similar between recipients with and without
onor lesions (p  1.0). During the three-year follow-up,
epeat transplantation was performed in only one patient, who
id not have baseline donor lesions but in whom severe TCAD
eveloped at the first year after transplantation.
ISCUSSION
he IVUS data in this study showed that 30% of recipients
ad donor lesions defined as a maximum intimal thickness
0.5 mm at baseline IVUS examination. At the first year
fter transplantation, 8% of the sites with donor lesions
howed progression of donor lesions, 3% showed regression
f donor lesions, and 89% had an absolute change0.5 mm
n maximum intimal thickness. Most importantly, the current
tudy found by IVUS imaging that the presence of pre-existing
onor atherosclerosis does not accelerate the development of
ardiac allograft vasculopathy either at the site of pre-existing
onor lesions or elsewhere within the same artery, however,
atients with pre-existing donor atherosclerosis have a
igher degree of angiographic coronary artery narrowing
uring the three-year follow-up. This seems to be paradox-
cal, but it can be explained by the differences in the
bservational techniques of IVUS versus angiography.
Intravascular ultrasound is more sensitive than coronary
ngiography in detecting donor atherosclerosis (13). In
ddition, the use of serial IVUS detects not only early
evelopment of cardiac allograft vasculopathy but also the
ate of progression of this disease (14,15). It is important to
istinguish the definition of cardiac allograft vasculopathy
y IVUS versus angiography because these two examina-
ions show different phenomena in the development of
ardiac allograft vasculopathy. By IVUS, the development
f cardiac allograft vasculopathy is defined as an increase in
igure 2. Kaplan-Meier estimate of freedom from angiographic transplant
oronary artery disease (TCAD) by three years after transplantation.
ecipients with donor lesions: n  89; recipients without donor lesions:
 212.aximal intimal thickness of at least 0.5 mm from baseline.
a
ln contrast, the angiographic evidence of TCAD is defined
y luminal narrowing, which can be caused by a combina-
ion of pre-existing donor atherosclerosis and new lesions
hat develop after transplantation. The observation from
VUS that donor lesions do not have a greater rate of
ntimal progression after transplantation can be reconciled
ith angiographic reports that hearts with donor lesions
evelop more TCAD is shown in Figure 3. The threshold
f a 50% diameter stenosis will be reached sooner in arteries
ith donor lesions, despite the observations by IVUS that
he rate of progression of cumulative cross-sectional area
tenosis is similar. Consistent with previous studies (9,16),
he current study found that patients with pre-existing
onor atherosclerosis have more severe coronary artery
arrowing up to three years after transplantation not be-
ause they progress more rapidly but because they start at a
reater percentage of stenosis.
In the serial examinations by IVUS, the first year data
howed that the average increase in maximum intimal
hickness was lower in sites with donor lesions than in sites
ithout donor lesions; in contrast, the three-year data
howed that no significant difference was noted for the
hange in intimal thickening between sites with or without
onor lesions. Other studies have also shown a similar or
lower progression of intimal hyperplasia in sites with donor
esions compared with sites without donor lesions (14,16–
9). These results suggest that pre-existing donor athero-
clerosis does not provide a nidus for accelerating intimal
rowth compared with sites without donor lesions. There-
ore, the presence of pre-existing donor atherosclerosis is
ot a trigger for the subsequent development of cardiac
llograft vasculopathy (16). In addition, there was no
ssociation between the progression of pre-existing donor
therosclerosis and the development of new lesions within
he same artery in the present study (17). After transplan-
ation, all of the coronary arteries of the donor heart are
igure 3. The cumulative cross-sectional area of stenosis at sites with and
ithout donor lesions by three years after transplantation. DL  donor
esions; Sites Without DL (1)  sites without donor lesions but from
rteries with donor lesions; Sites Without DL (2)  sites without donor
esions from arteries without donor lesions.
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June 20, 2006:2470–6 Heart Transplant IVUS Studyxposed to the same immune and nonimmune environment,
hich might lead to a similar rate of progression of intimal
yperplasia at sites with or without pre-existing donor
therosclerosis.
Little is known about the influence of donor lesions on
ascular remodeling. This study found that sites with donor
esions did not show compensatory vessel enlargement as
urther intimal thickening developed. This observation sug-
ests that the presence of pre-existing donor lesions may
mpede compensatory expansive remodeling as intimal thick-
ning progresses (18,20). Expansive remodeling may be a
ompensatory mechanism in the early development of native
nd transplant atherosclerotic lesions, which prevents luminal
oss (21,22). The ability to undergo compensatory vessel
nlargement in the presence of plaque formation is dependent
n intact endothelial function (23). In sites with donor lesions,
ore endothelial cell dysfunction and adventitial fibrosis may
nhibit vessel enlargement as intimal thickening progresses
fter transplantation. One study has reported that early con-
triction of vessels caused an overall decrease in EEM area and
as associated with a greater lumen loss during follow-up (24).
onsequently, in patients with donor lesions, angiographic
CAD more frequently develops (defined as 50% diameter
tenosis) because of a lack of expansive remodeling and
re-existing luminal stenosis.
The mechanism of the development of cardiac allograft
asculopathy is not fully understood but is likely a conse-
uence of both long-acting immunologic rejection and
onimmunologic factors, such as hyperlipidemia, hyperten-
ion, and hyperglycemia (3,4). Previous studies have shown
hat statin treatment is associated with lower risks of death,
erious rejection, and the development of cardiac allograft
asculopathy (25–27). Mycophenolate mofetil was more
fficacious than azathioprine in reducing progression of
ardiac allograft vasculopathy and improving survival among
eart transplant recipients (28,29). In the present study
here was no difference in the use of statin and azathioprine,
otal cholesterol levels, the incidence of diabetes and hyper-
ension, cytomegalovirus infection, and acute allograft re-
ection between patients with and without donor lesions.
The influence of pre-existing donor lesions on clinical
utcomes is unclear. The mean age of donors in this study
as 29.6 years. As expected, the mean age in hearts with
onor lesions (39.5 years) was 14 years older than
ransplant hearts without donor lesions (25.4 years). One
tudy evaluated 479 adult heart transplant recipients and
ound that the correlation between older donor age (40
ears) and poor survival was confined within the first
ost-transplantation month (10). Consistent with previous
eports (9,30), the present study also found that in recipients
ho survived beyond the first post-transplantation year,
re-existing donor lesions did not affect the survival of heart
ransplants up to three years after OHT. Similarly, recent
tudies describe that the presence of donor lesions by IVUS
as not predictive of adverse outcomes (31), whereas rapid
rogression of intimal thickening in the first year after eransplantation (an increase of 0.5 mm in MIT from
aseline to one-year measurement, including progression of
onor lesions and new lesions) predicts all-cause mortality,
onfatal myocardial infarction, and the subsequent devel-
pment of angiographically severe coronary artery disease
31,32).
Intravascular ultrasound has been recognized as the most
ensitive diagnostic tool for early detection of cardiac
llograft vasculopathy, but remains an invasive procedure,
hus limiting its widespread use (33). A recent study argued
hat multislice computed tomography may be more sensitive
han conventional coronary angiography for detecting thick-
ned segments in heart transplant patients (34). However,
uture research is needed to determine whether IVUS
xaminations can be replaced by multislice computed to-
ography in heart transplant patients.
tudy limitations. This study did not analyze the influence
f pre-existing donor lesions on the first-year mortality in
eart transplant recipients because only patients who sur-
ived beyond the first post-transplantation year were in-
luded in the present study. The small number of mortality
nd points is inherent to serial IVUS studies. The IVUS
maging was performed in only one coronary artery per
atient in 276 (92%) of the 301 cardiac transplant recipi-
nts. This may affect the reported incidence of pre-existing
onor lesions and development of cardiac allograft vascu-
opathy. All IVUS images were performed with manual
ullback of the IVUS catheter because motorized pullback
evices were not available during the period of this study.
his could lead to difficulty in matching sites from the
aseline and follow-up studies. Volumetric analysis of
laque burden by automated pullback of the IVUS catheter
ay avoid the problems associated with matching individual
ites, however, variability in the pullback length between
onsistent angiographic markers such as bifurcations can
roduce errors in volumetric analyses.
onclusions. Assessing the influence of pre-existing donor
therosclerosis on the development of cardiac allograft
asculopathy is complex, and the pathophysiological mech-
nisms are not fully understood. This three-year serial IVUS
tudy shows that pre-existing donor atherosclerosis does not
ct as a nidus for accelerating the progression of intimal
yperplasia. The presence of a donor lesion as a marker of a
eart that existed in an atherosclerotic environment also
oes not predispose to the development of new lesions
lsewhere in the same artery after transplantation. Donor
esions may impede compensatory expansive remodeling as
ntimal thickening progresses. The use of older hearts with
re-existing donor atherosclerosis is associated with an
ncrease in the angiographic incidence of TCAD up to three
ears after transplantation not because the rate of progres-
ion of cardiac allograft vasculopathy is greater, but because
he donor lesion starts from a position that is more nar-
owed at the time of transplantation. In recipients who
urvived beyond the first post-transplantation year, pre-
xisting donor atherosclerosis did not affect the long-term
s
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ransplantation. This study suggests that the selective use of
onor hearts with mild coronary artery disease is an accept-
ble option for cardiac transplantation.
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